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Abstract
Background—Hypertension is the most prevalent comorbidity in individuals with chronic
kidney disease (CKD). It is unknown, however, whether the association of the CKD measures,
estimated glomerular filtration rate (eGFR) and albuminuria, with mortality or end-stage renal
disease (ESRD) differs by hypertensive status.
Methods—We performed a meta-analysis of 45 cohorts (25 general population, 7 high-risk and
13 CKD cohorts), including 1,127,656 participants (364,344 with hypertension). Adjusted hazard
ratios (HRs) for all-cause mortality (84,078 deaths from 40 cohorts) and ESRD (7,587 events from
21 cohorts) by hypertensive status were obtained for each study and pooled using random-effects
models.
Findings—Low eGFR and high albuminuria were associated with mortality in both non-
hypertensive and hypertensive individuals in the general population and high-risk cohorts.
Mortality risk was higher in hypertensives as compared to non-hypertensives at preserved eGFR
but a steeper relative risk gradient among non-hypertensives than hypertensives at eGFR range
45-75 ml/min/1.73m2 led to similar mortality risk at lower eGFR. With a reference eGFR of 95
mL/min/1.73m2 in each group to explicitly assess interaction, adjusted HR for all-cause mortality
at eGFR 45 mL/min/1.73m2 was 1.77 (95% CI, 1.57-1.99) in non-hypertensives versus 1.24
(1.11-1.39) in hypertensives (P for overall interaction =0.0003). Similarly, for albumin-creatinine
ratio (ACR) of 300 mg/g (vs. 5 mg/g), HRs were 2.30 (1.98-2.68) in non-hypertensives versus
2.08 (1.84-2.35) in hypertensives (P for overall interaction=0.019). Similar results were observed
for cardiovascular mortality. The associations of eGFR and albuminuria with ESRD, however, did
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not differ by hypertensive status. Results in CKD cohorts were comparable to results in general
and high-risk population cohorts.
Interpretation—Low eGFR and elevated albuminuria were more strongly associated with
mortality among individuals without hypertension than in those with hypertension, but the
associations with ESRD were similar. CKD should be considered at least an equally relevant risk
factor for mortality and ESRD in non-hypertensive as it is in hypertensive individuals.
Funding—The US National Kidney Foundation (sources include Abbott and Amgen).
Introduction
Chronic kidney disease (CKD) is a major health problem, affecting 10 to 16% of the general
adult population in Asia, Europe, Australia and the USA,1-6 and is associated with increased
risk of mortality, cardiovascular disease and progression to renal failure.6-10 Reduced
glomerular filtration rate (GFR) and elevated albuminuria, the two key kidney measures for
CKD definition,1 frequently coexist with traditional cardiovascular risk factors, with
hypertension being the most common.5, 11 The prevalence of hypertension ranges from
approximately 22% in stage 1 to over 80% in stage 4 CKD.5,11 Prevalence of hypertension
increases with both decreased GFR and elevated albuminuria.11 Whereas screening for CKD
in the general population setting is a matter of debate,12 screening high-risk individuals such
as hypertensives is recommended by current guidelines.13-15
Since hypertension is not only a cause but also a consequence of CKD,16 one may expect
that hypertensive individuals encounter a vicious circle of hypertension-CKD interrelation
and therefore have stronger CKD-risk associations. Reliable data directly comparing key
kidney measures with either mortality or end-stage renal disease (ESRD) in hypertensive
versus non-hypertensive individuals, however, is lacking.17 In fact, the presence of CKD has
been proposed as a marker of hypertension and other traditional cardiovascular risk factors
such as diabetes, with questionable relevance in the absence of traditional cardiovascular
risk factors.17, 18 Hence, data evaluating associations of reduced eGFR and elevated
albuminuria with mortality and ESRD in absence versus presence of hypertension will
provide important insights for patient-care and public health. We report results of a large-
scale meta-analysis evaluating whether hypertensive status modifies the association of
decreased eGFR and increased albuminuria with all-cause and cardiovascular mortality and
ESRD.
Methods
Study selection criteria
Details of the study selection of the Chronic Kidney Disease Prognosis Consortium (CKD-
PC) are presented elsewhere.6-10, 19 Briefly, to be included in the Consortium, a general
population or a high-risk cohort (i.e. cohorts selected on the basis of cardiovascular disease
or cardiovascular risk factors) had to have at least 1000 participants, with baseline
information on estimated GFR (eGFR) and albuminuria, and either mortality or ESRD, with
a minimum of 50 events. The eligibility criterion for cohorts enrolling exclusively
individuals with CKD was similar, except that studies with fewer than 1000 participants
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were included. This study was approved by the institutional review board at the Johns
Hopkins Bloomberg School of Public Health.
Exposures, effect modifier and outcome variables definitions
We used the CKD Epidemiology Collaboration (CKD-EPI) equation to estimate GFR from
age, sex, race, and serum creatinine concentration.20 In studies where serum creatinine was
not standardized to isotope dilution mass spectrometry (IDMS), we utilized a previously
established calibration factor, that is, reduction of creatinine levels by 5%.21 Albuminuria
was ascertained by albumin-to-creatinine ratio (ACR), urine albumin excretion rate, protein-
to-creatinine ratio (PCR) or quantitative dipstick.
Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure
≥90 mm Hg, or use of antihypertensive medication in the general and high-risk population
cohorts. In primary analyses of CKD cohorts, hypertension status was categorized only by
the aforementioned systolic and diastolic blood pressure values, because antihypertensive
medication was used in ≥97% of participants in 4 cohorts and information on
antihypertensive medication was not available in 1 cohort. Other categorizations of
hypertension status used in sensitivity analyses are shown in supplementary Appendix page
40.
Outcomes of interest were all-cause and cardiovascular disease (CVD) mortality, and ESRD.
Cardiovascular mortality was defined as death due to myocardial infarction, heart failure,
stroke, or sudden cardiac death. ESRD was defined as start of renal replacement therapy or
death coded as due to kidney disease other than acute kidney injury.
Covariates
History of cardiovascular disease was defined as previous myocardial infarction, coronary
revascularization, heart failure, or stroke. Diabetes mellitus was defined as fasting glucose
concentration ≥7.0 mmol/L (≥126 mg/dL), non-fasting glucose concentration ≥11.1 mmol/L
(≥200 mg/dL) or hemoglobin A1c ≥ 6.5%, or use of glucose lowering drugs or self-reported
diabetes. Smoking was dichotomized to current smokers versus former or never-smokers.
Body mass index (BMI) was calculated as body weight in kilograms divided by height in
meters squared.
Statistical analysis
Investigators from each study were asked to either send individual-level data to the data
coordination center (Johns Hopkins University, Baltimore, MD) or analyze their data in
accordance with an analytical plan using centrally developed statistical code. Subjects with
missing values for either eGFR or albuminuria were excluded. Whereas, values of the effect-
modifier (hypertensive status or blood-pressure) were not imputed, missing values for all
other covariates were imputed using simple mean imputation. The analysis overview and
analytic notes for individual studies are described in the supplementary Appendix page 39.
Cox proportional hazards models were used to estimate the hazard ratios (HRs) of mortality
and ESRD associated with eGFR and albuminuria in hypertensive versus non-hypertensive
individuals, adjusted for age, sex, race (black vs. non-black), history of cardiovascular
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disease, diabetes, serum total cholesterol (continuous), BMI (continuous), smoking, and
albuminuria (log-transformed ACR or PCR as continuous variables or dipstick proteinuria as
categorical variable) for eGFR analysis or eGFR splines for ACR analysis.
In each study, eGFR linear splines (knots at each 15 ml/min/1.73m2 from 30 to 105 ml/min/
1.73m2 [90 ml/min/1.73m2 in CKD cohorts]) and their product terms with hypertension
were fitted, providing HRs for eGFR (relative to the reference eGFR = 95 mL/min/1.73m2
in general and high risk cohorts and eGFR = 50 mL/min/1.73m2 in CKD cohorts) in both
non-hypertensive and hypertensive groups. From this model, the interaction was evaluated
as the ratio of HRs in hypertensive versus non-hypertensive at each 1 mL/min/1.73m2 of
eGFR from 15 to 120 mL/min/1.73m2 (point-wise interaction). HRs and ratios of HRs for
each eGFR value and their standard errors were obtained in each cohort and then pooled
using random effects meta-analysis. To assess overall interaction over the total range of
eGFR, the coefficients of the product terms of eGFR splines and hypertension status were
pooled using inverse-variance weighting. The same approach was applied to ACR risk
association, with knots at 10, 30, and 300 mg/g and a reference at ACR = 5 mg/g in the
general and high-risk populations and knots at 30, 300, 1000 mg/g and reference at ACR =
100 mg/g in CKD cohorts. Point-wise interaction of the ACR-risk association was assessed
at approximate 8% increments of ACR. Finally, to visualize the impact of hypertension on
the risk of mortality and ESRD, risk estimates of both hypertensive and non-hypertensive
groups were compared to a single reference point of eGFR=95 (50 in CKD cohorts)
mL/min/1.73m2 and ACR=5 (100 in CKD cohorts) mg/g of non-hypertensive individuals.
We also performed categorical analyses by comparing the risk in 32 categories of eGFR
(<15, 15-29, 30-44, 45-59, 60-74, 75-89, 90-104, ≥105 mL/min/1.73m2) and albuminuria
(ACR: <10, 10-29, 30-299, ≥300 mg/g; PCR <15, 15-49, 50-499, ≥500 mg/g; or dipstick test
results: negative, trace, 1+, 2+ or more), in general and high-risk cohorts. In CKD cohorts,
the categorical analysis was based on 20 categories of eGFR (<15, 15-29, 30-44, 45-74, ≥75
mL/min/1.73m2) and albuminuria (ACR <30, 30-299, 300-999, ≥1,000 mg/g; PCR <50,
50-499, 500-1,499, ≥1,500 mg/g; or dipstick test results: negative/trace, 1+, 2+, 3+ or more).
Heterogeneity of the pooled estimates was assessed by the χ2 test for heterogeneity and the
I2 statistic. In all analyses, a P value of less than 0.05 was considered significant. All
analyses were done with Stata 11.2 (www.stata.com).
Results
Overall, 742,240 participants without hypertension and 347,256 with hypertension were
followed for 6,277,878 and 2,970,318 person-years in the combined general (25 cohorts)
and high-risk populations (7 cohorts), respectively (Table 1). In the CKD cohorts, 21,072
participants without hypertension and 17,088 with hypertension were followed for 86,970
and 72,299 person-years, respectively. The mean age of participants and the prevalence of
traditional cardiovascular risk factors, especially diabetes, was higher in hypertensive
individuals (Table 1 and supplementary Table 1). Due to similarity in range of eGFR and
albuminuria (Table 1) and risk, general population and high-risk cohorts were combined in
the primary meta-analysis.
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All-cause and cardiovascular mortality
Of the general population and high-risk cohorts, 30 studies had data on all-cause mortality
(27,836 deaths [cumulative incidence, 4.1%] in non-hypertensives vs. 47,335 [15.0%] in
hypertensives) and 23 studies had data on cardiovascular mortality (6,601 deaths [0.9%] in
non-hypertensives vs. 15,634 deaths [6.8%] in hypertensives) (supplemental Table 1). With
a reference at eGFR 95 mL/min/1.73m2 among non-hypertensives, hypertensives had a
higher risk of mortality in the eGFR range of above ∼55 for all-cause and ∼45 mL/min/
1.73m2 for cardiovascular mortality (Figure 1, A and C). However, non-hypertensives
demonstrated a steeper relative risk gradient at the eGFR range 45-75 ml/min/1.73m2, and
their risk of mortality outcomes was similar or even higher as compared to hypertensives at
eGFR below ∼45 ml/min/1.73m2. When separate references were set at eGFR of 95
mL/min/1.73m2 in both hypertensive and non-hypertensive groups to explicitly depict
eGFR-hypertension interaction (Figure 1 B and D), significant point-wise interaction at
eGFR levels below 59 mL/min/1.73m2 for all-cause mortality and below 73 mL/min/1.73m2
for cardiovascular mortality. The overall interaction of hypertension with eGFR was
significant for all-cause mortality (average relative HR for 15ml/min/1.73m2 lower eGFR
between hypertensives vs. non-hypertensives 0.95 [95% CI, 0.92-0.98], P for overall
interaction = 0.0003) and cardiovascular mortality (average relative HR 0.89 [0.83-0.96], P
for overall interaction = 0.0004). Although we observed moderate heterogeneity of the
overall interaction for all-cause (I2=56%) and cardiovascular mortality (I2= 66%), most
cohorts were in agreement with a weaker association for low eGFR in hypertensives
compared to non-hypertensives (relative HR <1.0, supplemental Figure 1).
Higher ACR was associated with greater risk of all-cause and cardiovascular mortality
among both non-hypertensive and hypertensive individuals (Figure 2). Individuals with
hypertension had higher mortality risk compared to those without hypertension at ACR
below ∼100 mg/g (Figure 2A and C). However, non-hypertensives had a steeper relative
risk gradient in the ACR range >30 mg/g, and their mortality risk was comparable or even
higher as compared to hypertensives at ACR values above ∼100 mg/g. With separate
references at ACR of 5 mg/g in each group, significant point-wise interaction was observed
in the ACR range above 300 mg/g for all-cause mortality and above100 mg/g for
cardiovascular mortality (Figure 2 B and D). Overall interaction was significant for all-cause
mortality (average relative HR for 10-fold higher ACR 0.91 [95% CI, 0.83-0.98], P for
overall interaction = 0.019) but did not reach significance for cardiovascular mortality (0.87
[0.74-1.03], P for overall interaction =0.11). The majority of studies showed a stronger risk
association for ACR in non-hypertensives compared to hypertensives with low
heterogeneity (I2=14% all-cause mortality and 0% for cardiovascular mortality)
(supplemental Figure 2).
The risk of all-cause and cardiovascular mortality increased with lower eGFR and higher
albuminuria categories for both non-hypertensive and hypertensive individuals (Table 2).
The association of eGFR and albuminuria categories with risk of all-cause and
cardiovascular mortality was generally stronger in non-hypertensives as compared to
hypertensives, with significant interaction observed in eGFR categories <60 (<75 for
cardiovascular mortality) mL/min/1.73m2 and in the albuminuria category of ACR ≥300
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mg/g or dipstick ≥2+. Supplemental Figures 3 through 6 show higher HRs of mortality
outcomes in non-hypertensives compared to hypertensives for the eGFR category of 30-44
mL/min/1.73m2 (vs. 90-104) and albuminuria category of ACR ≥300 mg/g or dipstick ≥2+
(vs. ACR<10 or dipstick -), with mild to moderate heterogeneity across cohorts (I2 ranging
from 22.5% to 40.1%, P from 0.037 to 0.17).
Largely similar results were observed when the general population with ACR and dipstick
and high-risk cohorts were analyzed separately (Supplemental Figures 7 and 8). In analyses
categorizing individuals as normotensives (systolic/diastolic blood pressure <120/80
mmHg), pre-hypertensives (systolic/diastolic blood pressure 120-139/80-89 mmHg),
controlled (systolic/diastolic blood pressure <140/90 mmHg under antihypertensive drugs
use) and uncontrolled hypertensives (systolic/diastolic blood pressure ≥140/90, we observed
the strongest risk associations in normotensives and the weakest risk association in
uncontrolled hypertensives (supplemental Figure 9). Subdivision of the hypertensive group
into treated versus untreated hypertensives resulted in similar risk associations in each
hypertension category (supplemental Figure 10). When hypertensive status was defined by
only blood pressure values (systolic/diastolic blood pressure ≥140/90 mmHg, supplemental
Figure 11), or systolic and diastolic blood pressures were modeled as continuous variables,
consistently stronger CKD-mortality associations were observed at lower blood pressure
(supplemental Figures 12-15).
Finally, in CKD cohorts the associations of eGFR and albuminuria with mortality outcomes
were largely comparable to the results of the combined general population and high-risk
cohorts (supplemental Figure 16). Association of ACR with mortality was less steep in both
non-hypertensive and hypertensive groups in the CKD cohorts than in the respective
combined general population and high-risk cohorts.
End-stage renal disease
In the 5 general population and high-risk cohorts with information on antihypertensive
drugs, blood pressure, and incident ESRD (282 ESRD events [cumulative incidence, 1.0%]
in non-hypertensives vs. 807 events [2.1%] in hypertensives), low eGFR and high ACR
were associated with higher risk of ESRD in both non-hypertensives and hypertensives
(supplemental Figure 17). Although significant interaction was observed in the range of
eGFR 55 to 72 ml/min/1.73m2 (higher HR for eGFR in hypertensives than in non-
hypertensives), the test for overall interaction did not reach significance (P=0.07). Moreover,
the eGFR-ESRD relationship also was comparable in analyses categorizing hypertension
status based only on blood pressure, without taking antihypertensive treatment into account
(supplemental Figure 18, P for overall interaction=0.20). Neither point-wise nor overall
interaction of ACR with hypertensive status on ESRD was significant (P for overall
interaction=0.92, supplemental Figure 17).
In the 13 CKD cohorts with a total of 5,924 ESRD events (2,597 events [cumulative
incidence, 13.9%] in non-hypertensives; 3,327 events [9.7%] in hypertensives), a clear dose-
response association of low eGFR and high ACR with ESRD was observed in both the non-
hypertensive and hypertensive groups (Figure 3). These associations did not differ by
hypertensive status (P for overall interaction=0.42 for eGFR and 0.64 for ACR). Similarly,
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categorical analyses of eGFR and albuminuria did not demonstrate interaction of
hypertensive status with either eGFR or albuminuria (Table 3). Likewise, no significant
interaction was observed in analyses incorporating antihypertensive medication use in the
definition of hypertension (supplemental Figure 19).
Stratified analyses
The stronger eGFR-mortality association in non-hypertensives as compared to hypertensives
was more evident in the absence of diabetes (Figure 4 and supplemental Figure 20). Similar
attenuation in diabetics was not observed for the ACR association with mortality outcomes
(supplemental Figures 21 and 22). There was no significant interaction of hypertensive
status with either eGFR or ACR for the associations with ESRD among individuals with or
without diabetes in the CKD cohorts (supplemental Figures 23 and 24).
Finally, stratified analyses according to gender, age (< vs. ≥65 years), and history of
cardiovascular disease for all-cause mortality demonstrated that there was a more
pronounced multiplicative interaction of eGFR and ACR with hypertensive status in the
lower risk strata (i.e., age <65 years, no history of cardiovascular disease) (supplemental
Figures 25 and 28). One exception was gender where higher risk in non-hypertensives was
more evident in males compared to females (supplemental Figures 29 and 30). This was
particularly the case for ACR, as the higher risk of all-cause mortality in non-hypertensives
versus hypertensives was only observed in males.
Discussion
In this meta-analysis of 1,089,496 participants from 32 general and high-risk populations,
low eGFR and high ACR showed dose-dependent associations with all-cause and
cardiovascular mortality and ESRD in both non-hypertensive and hypertensive individuals.
The associations of eGFR and ACR with mortality outcomes were stronger in non-
hypertensives as compared to hypertensive individuals, whereas the eGFR and ACR
associations with ESRD did not differ by hypertensive status. Dose-dependent associations
of low eGFR and high ACR also were observed in the 13 CKD cohorts with 38,160
participants. In these cohorts, however, neither the associations with mortality nor with
ESRD differed by hypertensive status. The observed interaction of eGFR and ACR with
mortality outcomes in the general and high-risk population cohorts was not due to presence
of diabetes. Interaction of the kidney measures with diabetes is explicitly assessed in the
accompanying paper.22
A few studies have reported a stronger association of eGFR with mortality in non-
hypertensive individuals as compared to hypertensive individuals.23-26 Although in our
analysis individual studies were frequently underpowered to detect statistically significant
interaction between hypertension and eGFR, the direction of the effect modification were
largely consistent across cohorts. The interaction of low eGFR with hypertension on
mortality outcomes was mainly driven by a steeper association of eGFR with mortality
outcomes in non-hypertensives in the preserved eGFR range down to eGFR of
approximately 45 mL/min/1.73m2. In the eGFR range below 45 ml/min/1.73m2, low eGFR
showed similar relative risk gradient for mortality outcomes in both non-hypertensive and
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hypertensives. This finding was consistent in the three types of cohorts (general population,
high-risk, and CKD cohorts). A previously reported J-shaped association between eGFR and
mortality (i.e., paradoxically increased risk at higher eGFR)19 was observed in both non-
hypertensives and hypertensives, particularly in older individuals, probably inherent to
creatinine-based eGFR equations reflecting muscle-wasting in some individuals.
We also observed stronger association of albuminuria with mortality outcomes among non-
hypertensives compared to hypertensives. Unlike eGFR, the association between ACR and
mortality outcomes and ESRD was monotonic without J-shape in both hypertension and
non-hypertension groups. This would be a nice property for ACR in terms of risk prediction,
although further studies are required to assess its usefulness for improvement in risk
prediction.27 Although, ACR is considered a more sensitive and thus preferable method in
clinical and laboratory guidelines.1, 28 we observed similar interaction of hypertension on
mortality when we combined ACR and dipstick proteinuria categories (Table 2).
The association of eGFR and ACR with ESRD was similar in hypertensive versus non-
hypertensive individuals in all three types of cohorts. The increased risk of ESRD conferred
by CKD in hypertensives might be attenuated by antihypertensive treatment.29 In the CKD
cohorts, the majority of participants were on antihypertensive treatment which led us to
classify study-participants as hypertensive based on blood pressure values only.
Nevertheless, in sensitivity analysis of a subset of CKD cohorts with sufficient number of
participants with normal blood pressure not using antihypertensive drugs, incorporation of
antihypertensive medication use in the definition of hypertension showed similar results.
Possible explanations for the relatively stronger association of low eGFR and high ACR
with mortality in non-hypertensive as compared to hypertensive individuals include
comorbid conditions such as changes in cardiac structure or function (e.g., heart failure)30, 31
and autonomic dysregulations,32 that predispose for mortality and can limit blood pressure
increase. However, sensitivity analysis stratified by history of cardiovascular disease, that
also incorporated heart failure, did not demonstrate any evidence for an influence of prior
cardiovascular disease on the observed interaction. Nevertheless, we cannot deny the
involvement of undiagnosed heart failure. It is also possible that low eGFR and high ACR in
non-hypertensives are due to etiologies with a worse prognosis (e.g., glomerulonephritis).
Moreover, antihypertensive treatment may affect levels of serum creatinine and albuminuria
and reduce the risk of mortality,33, 34 to some extent independent of blood pressure
lowering,34 and may contribute to this interaction. However, largely similar associations of
eGFR and ACR with mortality outcomes by hypertensive status were observed when we
compared treated versus untreated hypertension. Nevertheless, we should not interpret that
antihypertensive treatment has no effect on the risk reduction, since there is possibility of
bias by treatment indication in observational studies (e.g., high-risk individuals with long-
term hypertension are likely to be treated).
These results provide evidence that the association of low eGFR and high albuminuria with
mortality and ESRD in non-hypertensive individuals is stronger or equal to the associations
in hypertensive individuals. This was consistently demonstrated when we treated the key
exposures (eGFR and ACR) and the effect modifier (blood pressure) as continuous and
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categorical variables. Our findings suggest that CKD warrants attention and management
irrespective hypertension status. Nevertheless, we caution against over-interpretation of
these results, which are based on observational studies.
This study has several limitations. Measurements of creatinine, albuminuria and blood
pressure were not standardized across all studies. Some studies measured creatinine and
albuminuria in fresh samples, whereas other studies used frozen samples. Majority of studies
with dipstick albuminuria measurements were from Asia, and general population-based
studies with ACR mainly consists of whites. Nevertheless, analyses by cohort type showed
comparable results. Also, our consortium relatively underrepresents blacks, particularly
from Africa, and most of them were from cohorts in the US. Information on the number of
antihypertensive drugs, duration of antihypertensive treatment, diet and exercise were not
included. Finally, given that our results were primarily based on observational cohorts, there
is a possibility of residual confounding. Finally, future studies are needed to assess whether
any cause-specific mortality is driving the all-cause mortality interaction.
In conclusion, in this large-size pooled analysis, the eGFR and ACR associations with all-
cause and cardiovascular mortality were similar or even stronger in non-hypertensive
individuals as compared to hypertensive individuals. The presence of CKD in non-
hypertensive individuals should be considered at least an equally relevant risk factor for
mortality and ESRD as it is in hypertensive individuals.
Panel: Research in context
Systematic review—Given the high prevalence of chronic kidney disease (CKD) in
hypertensive individuals, clinical guidelines recommend screening for CKD in hypertensive
individuals.13-15 However, whether the association of CKD with cardiovascular disease or
mortality in hypertensive versus non-hypertensives is similar or not is unknown. Electronic
searches (e.g., PubMed) revealed only a few studies that focused on the association of blood
pressure values with mortality outcomes in subjects with CKD.23-26
We meta-analyzed individual-level data from 45 cohorts with over 1 million participants to
compare mortality and end-stage renal disease risk in hypertensive versus non-hypertensive
individuals. The participating cohorts were categorized as general population, high-risk
population and CKD population. Although details on the emergence of the CKD Prognosis
Consortium are published elsewhere,6-10 briefly, these studies were identified by electrical
searches, discussion between investigators, and a call for participation through a published
position statement of KDOQI and KDIGO and the KDIGO website (www.kdigo.org).6
Interpretation—CKD association was stronger with all-cause and cardiovascular mortality
among individuals without hypertension than in those with hypertension, but the
associations with ESRD were similar.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hazard ratios of all-cause and cardiovascular mortality according to eGFR in non-hypertensives (black-line) versus
hypertensives (red-line)
Panels A through D represents results of all-cause (A and B) and cardiovascular (C and D) mortality in the combined general
and high-risk populations. Panels A and C use eGFR of 95 mL/min/1.73m2 among non-hypertensive as a single reference point
(diamond) for both hypertensive and non-hypertensive individuals to visualize the main effect of hypertension on risk. Panels B
and D use eGFR of 95 mL/min/1.73m2 among hypertensives and non-hypertensives as the reference point (diamond) for
hypertensives and non-hypertensives to visualize interaction between eGFR and hypertensive status, respectively.. Significant
interaction between hypertension and eGFR is represented by “x” signs on the bottom of the right panels. Hazard ratios were
adjusted for age, sex, race, smoking, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body
mass index, and albuminuria (log-ACR, log-PCR or categorical dipstick proteinuria [negative, trace, 1+, ≥2+])
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Figure 2. Hazard ratios of all-cause and cardiovascular mortality according to ACR in non-hypertensives (black-line) versus
hypertensives (red-line)
Panels A through D represents results of all-cause (A and B) and cardiovascular (C and D) mortality in the combined general
and high-risk populations. Panels A and C use ACR of 5 mg/g among non-hypertensive as a single reference point (diamond)
for both hypertensive and non-hypertensive individuals to visualize the main effect of hypertension on risk. Panels B and D use
ACR of 5 mg/g among hypertensives and non-hypertensives as the reference point (diamond) for hypertensives and non-
hypertensives to visualize interaction between ACR and hypertensive status, respectively. Significant interaction between
hypertension and ACR is represented by “x” signs in the right panels. Hazard ratios were adjusted for age, sex, race, smoking,
history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and eGFR splines.
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Figure 3. Hazard ratios of ESRD according to eGFR and ACR in non-hypertensives (black-line) versus hypertensives (red-line)
Panels A and B shows eGFR association with ESRD and panels C and D shows ACR association with ESRD in CKD cohorts.
Left panels use eGFR of 50 mL/min/1.73m2 (B) and ACR of 5 mg/g (C) among non-hypertensive as a single reference point
(diamond) for both hypertensive and non-hypertensive individuals. Right panels use eGFR of 50 mL/min/1.73m2 (A) and ACR
of 100 mg/g (C) as the reference points (diamond) in each hypertensive and non-hypertensive groups, respectively. Because
there were few participants with eGFR >60 mL/min/1.73m2 in the CKD cohorts by definition, the associations were only shown
below 60. Hazard ratios were adjusted for age, sex, race, smoking, history of cardiovascular disease, diabetes, serum total
cholesterol concentration, body mass index, and albuminuria (log-ACR, log-PCR or categorical dipstick proteinuria [negative,
trace, 1+, ≥2+]) or eGFR splines, as appropriate.
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Figure 4. Hazard ratios of all-cause mortality for eGFR in non-hypertensives (black-line) versus hypertensives (red-line) according to
diabetes status
Panels A through D show eGFR association with all-cause mortality in non-diabetics (panel A and B) versus diabetics (panel C
and D) in the combined general and high-risk populations. Significant interaction between hypertension and eGFR is
represented by “x” signs. Hazard ratios were adjusted for age, sex, race, smoking, history of cardiovascular disease, serum total
cholesterol concentration, body mass index, and albuminuria (log-ACR, log-PCR or categorical dipstick proteinuria [negative,
trace, 1+, ≥2+]).
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